Paper Details

  1. Home
  2. Paper Details

Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine.

Author: AppelbergBjörn, JoffeGrigori, TuiskuKatinka

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the effects of olanzapine and conventional antipsychotics in treating schizophrenia. Olanzapine was found to be more effective in reducing both psychotic symptoms and neurological side effects.
Paper Details　
Original Abstract of the Article :
Fifty clinically stable, schizophrenic outpatients, suffering from residual schizophrenic symptoms and/or neurological side effects, were randomised to either continue their conventional neuroleptic(s) or change it to olanzapine. After 12 weeks patients on olanzapine exhibited significant improvemen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eurpsy.2004.06.035

データ提供：米国国立医学図書館（NLM）

Atypical Antipsychotics: A New Oasis for Schizophrenic Patients

The journey of living with [schizophrenia] is fraught with challenges, including [residual symptoms] and [side effects] from medication. This study investigated the potential benefits of switching from [conventional antipsychotics] to [atypical antipsychotics], specifically [olanzapine], for patients with [mild to moderate residual symptoms]. The researchers meticulously designed a [prospective, randomized study] to evaluate the effectiveness of this switch, much like a skilled desert explorer carefully plans their route to ensure success.

Olanzapine: A Potential Oasis for Schizophrenic Patients

The study revealed that patients who switched to [olanzapine] showed significant improvements in [neurological side effects] and [psychotic symptomatology] compared to those who continued on [conventional antipsychotics]. These findings suggest that [olanzapine] could provide a more effective and tolerable treatment option for [schizophrenia], offering a potential oasis in the sometimes-difficult landscape of this condition.

Navigating Schizophrenia with Olanzapine: Potential for Improved Quality of Life

This study suggests that switching to [atypical antipsychotics] like [olanzapine] could improve the quality of life for patients with [schizophrenia]. By reducing [side effects] and improving [symptom control], [olanzapine] could help patients navigate their condition with greater ease and potentially experience a more fulfilling life. It's like finding a refreshing spring in a parched desert, providing much-needed relief and support for those who need it.

Dr. Camel's Conclusion

This study offers a glimmer of hope for patients with [schizophrenia] who are struggling with [side effects] and [residual symptoms] from [conventional antipsychotics]. The findings suggest that switching to [atypical antipsychotics] like [olanzapine] could significantly improve their quality of life. It's a reminder that the journey of managing [schizophrenia] is an ongoing quest for better treatments and a more fulfilling life.

Date :
  1. Date Completed 2005-05-05
  2. Date Revised 2020-01-09
Further Info :

Pubmed ID

15589715

DOI: Digital Object Identifier

10.1016/j.eurpsy.2004.06.035

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.